The repeated failure of cytokine-targeted therapies such as anti-TNF, anti-IL-1, and anti-IL-6 antibodies in sepsis reflects systemic issues in trial design and patient selection rather than the absence of biologic relevance. This evidence concerns the gene IL6 and Sepsis.